Nancy Bartlett

Research output

Research output per year 1989 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2023

• 224 Article
• 35 Review article
• 20 Letter
• 8 Comment/debate
• 8 More
  • 4 Chapter
  • 4 Editorial

Research output per year

Research output per year

Search results

• 2017

  A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)

  Martin, P., Jung, S. H., Pitcher, B., Bartlett, N. L., Blum, K. A., Shea, T., Hsi, E. D., Ruan, J., Smith, S. E., Leonard, J. P. & Cheson, B. D., Nov 2017, In: Annals of Oncology. 28, 11, p. 2806-2812 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lenalidomide 100%
  • Follicular Lymphoma 92%
  • Rituximab 81%
  • Non-Hodgkin's Lymphoma 70%
  • Exanthema 21%
  67 Scopus citations

• Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma

  Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Timmerman, J. M., Stiff, P. J., Friedberg, J. W., Flinn, I. W., Goy, A., Hill, B. T., Smith, M. R., Deol, A., Farooq, U., McSweeney, P., & 20 othersMunoz, J., Avivi, I., Castro, J. E., Westin, J. R., Chavez, J. C., Ghobadi, A., Komanduri, K. V., Levy, R., Jacobsen, E. D., Witzig, T. E., Reagan, P., Bot, A., Rossi, J., Navale, L., Jiang, Y., Aycock, J., Elias, M., Chang, D., Wiezorek, J. & Go, W. Y., Dec 28 2017, In: New England Journal of Medicine. 377, 26, p. 2531-2544 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • axicabtagene ciloleucel 100%
  • Chimeric Antigen Receptors 69%
  • B-Cell Lymphoma 53%
  • Cell- and Tissue-Based Therapy 48%
  • T-Lymphocytes 31%
  3365 Scopus citations

• Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry

  Bartlett, N. L., Smith, M. R., Siddiqi, T., Advani, R. H., O’Connor, O. A., Sharman, J. P., Feldman, T., Savage, K. J., Shustov, A. R., Diefenbach, C. S., Oki, Y., Palanca-Wessels, M. C., Uttarwar, M., Li, M., Yang, J. & Jacobsen, E. D., Jul 3 2017, In: Leukemia and Lymphoma. 58, 7, p. 1607-1616 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Brentuximab Vedotin 100%
  • Lymphoma, Large B-Cell, Diffuse 70%
  • Progression-Free Survival 56%
  • Immunohistochemistry 43%
  • Computer-Assisted Image Processing 37%
  43 Scopus citations

• Emerging role of novel therapies in Hodgkin lymphoma: Proceed with caution

  Bartlett, N. L., Dec 8 2017, In: Hematology. 2017, 1, p. 317-323 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Brentuximab Vedotin 100%
  • Hodgkin Disease 64%
  • Programmed Cell Death 1 Receptor 22%
  • pembrolizumab 22%
  • Nivolumab 21%
  7 Scopus citations

• Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

  Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., Fenton, K., Huebner, D., Pinelli, J. M., Kennedy, D. A. & Shustov, A., Dec 21 2017, In: Blood. 130, 25, p. 2709-2717 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Brentuximab Vedotin 100%
  • Anaplastic Large-Cell Lymphoma 84%
  • Refractory 64%
  • Safety 53%
  • Stem Cells 18%
  158 Scopus citations

• Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

  Lee, Y. S., Liu, J., Fricano, K. A., Webb, E. M., Toolsie, D. R., Jones, S., Rhoads, J. A., Vij, R., Cashen, A. F., Abboud, C. N., Westervelt, P., Bartlett, N. L., Dipersio, J. F., Kreisel, F. H. & Lim, K. H., Dec 2017, In: Biology of Blood and Marrow Transplantation. 23, 12, p. 2199-2204 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphoma, Large B-Cell, Diffuse 100%
  • Stem Cell Transplantation 93%
  • Mutation 49%
  • Transplants 33%
  • Progression-Free Survival 32%
  7 Scopus citations

• Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma

  Martin, P., Chen, Z., Cheson, B. D., Robinson, K. S., Williams, M., Rajguru, S. A., Friedberg, J. W., van der Jagt, R. H., LaCasce, A. S., Joyce, R., Ganjoo, K. N., Bartlett, N. L., Lemieux, B., VanderWalde, A., Herst, J., Szer, J., Bar, M. H., Cabanillas, F., Dodds, A. J., Montgomery, P. G., & 4 othersPressnail, B., Ellis, T., Smith, M. R. & Leonard, J. P., Jul 2017, In: British Journal of Haematology. 178, 2, p. 250-256 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Bendamustine Hydrochloride 100%
  • Non-Hodgkin's Lymphoma 61%
  • Stem Cells 47%
  • Lymphoma 23%
  • Neoplasms 20%
  28 Scopus citations

• Magnetic resonance image guided radiation therapy for primary splenic diffuse large B-cell lymphoma: A teaching case

  Fischer-Valuck, B. W., Green, O., Mazur, T., Li, H., Chundury, A., Rao, Y. J., Bartlett, N. L., Mutic, S. & Huang, J., Jan 1 2017, In: Practical Radiation Oncology. 7, 1, p. e23-e26

  Research output: Contribution to journal › Article › peer-review
  2 Scopus citations

• Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R

  Giulino-Roth, L., O'Donohue, T., Chen, Z., Bartlett, N. L., LaCasce, A., Martin-Doyle, W., Barth, M. J., Davies, K., Blum, K. A., Christian, B., Casulo, C., Smith, S. M., Godfrey, J., Termuhlen, A., Oberley, M. J., Alexander, S., Weitzman, S., Appel, B., Mizukawa, B., Svoboda, J., & 12 othersAfify, Z., Pauly, M., Dave, H., Gardner, R., Stephens, D. M., Zeitler, W. A., Forlenza, C., Levine, J., Williams, M. E., Sima, J. L., Bollard, C. M. & Leonard, J. P., Dec 2017, In: British Journal of Haematology. 179, 5, p. 739-747 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • B-Cell Lymphoma 100%
  • Rituximab 65%
  • Vincristine 65%
  • Etoposide 64%
  • Prednisone 61%
  95 Scopus citations

• Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

  Locke, F. L., Neelapu, S. S., Bartlett, N. L., Siddiqi, T., Chavez, J. C., Hosing, C. M., Ghobadi, A., Budde, L. E., Bot, A., Rossi, J. M., Jiang, Y., Xue, A. X., Elias, M., Aycock, J., Wiezorek, J. & Go, W. Y., Jan 4 2017, In: Molecular Therapy. 25, 1, p. 285-295 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • axicabtagene ciloleucel 100%
  • CD19 Antigens 81%
  • Chimeric Antigen Receptors 69%
  • Refractory 53%
  • Cell- and Tissue-Based Therapy 48%
  459 Scopus citations

• Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma

  Krysiak, K., Gomez, F., White, B. S., Matlock, M., Miller, C. A., Trani, L., Fronick, C. C., Fulton, R. S., Kreisel, F., Cashen, A. F., Carson, K., Berrien-Elliott, M. M., Bartlett, N. L., Griffith, M., Griffith, O. L. & Fehniger, T. A., Jan 26 2017, In: Blood. 129, 4, p. 473-483 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Follicular Lymphoma 100%
  • Mutation 68%
  • Signal Transduction 63%
  • B-Lymphocytes 62%
  • Genes 32%
  121 Scopus citations

• Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials

  Smith, S. M., Pitcher, B. N., Jung, S. H., Bartlett, N. L., Wagner-Johnston, N., Park, S. I., Richards, K. L., Cashen, A. F., Jaslowski, A., Smith, S. E., Cheson, B. D., Hsi, E. & Leonard, J. P., Apr 1 2017, In: The Lancet Haematology. 4, 4, p. e176-e182

  Research output: Contribution to journal › Article › peer-review

  • idelalisib 100%
  • Lenalidomide 80%
  • Rituximab 65%
  • Mantle-Cell Lymphoma 52%
  • Lymphoma 50%
  71 Scopus citations
• 2016

  A phase I/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed/refractory lymphoma

  Evens, A. M., Balasubramanian, S., Vose, J. M., Harb, W., Gordon, L. I., Langdon, R., Sprague, J., Sirisawad, M., Mani, C., Yue, J., Luan, Y., Horton, S., Graef, T. & Bartlett, N. L., Mar 1 2016, In: Clinical Cancer Research. 22, 5, p. 1059-1066 8 p.

  Research output: Contribution to journal › Article › peer-review

  • abexinostat 100%
  • Histone Deacetylase Inhibitors 57%
  • Follicular Lymphoma 45%
  • Lymphoma 40%
  • Mantle-Cell Lymphoma 32%
  64 Scopus citations

• A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

  Flinn, I. W., Bartlett, N. L., Blum, K. A., Ardeshna, K. M., Lacasce, A. S., Flowers, C. R., Shustov, A. R., Thress, K. S., Mitchell, P., Zheng, F., Skolnik, J. M. & Friedberg, J. W., Feb 1 2016, In: European Journal of Cancer. 54, p. 11-17 7 p.

  Research output: Contribution to journal › Article › peer-review

  • fostamatinib 100%
  • Lymphoma, Large B-Cell, Diffuse 59%
  • B-Lymphocytes 12%
  • Syk Kinase 6%
  • Genotype 5%
  61 Scopus citations

• A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma

  Oak, E. & Bartlett, N. L., Jun 2 2016, In: Expert Opinion on Drug Safety. 15, 6, p. 875-882 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Brentuximab Vedotin 100%
  • Hodgkin Disease 64%
  • Safety 36%
  • Immunoconjugates 18%
  • Therapeutics 10%
  19 Scopus citations

• Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration

  Cheah, C. Y., Bröckelmann, P. J., Chihara, D., Moskowitz, A. J., Engert, A., Jerkeman, M., El-Galaly, T. C., Augustson, B., Vose, J., Bartlett, N. L., Villa, D., Connors, J. M., Feldman, T., Pinnix, C. C., Milgrom, S. A., Dabaja, B., Oki, Y. & Fanale, M. A., Sep 1 2016, In: American journal of hematology. 91, 9, p. 894-899 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hodgkin Disease 100%
  • Central Nervous System 72%
  • Combined Modality Therapy 15%
  • Databases 14%
  • Disease-Free Survival 11%
  13 Scopus citations

• Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome

  Nguyen, T. D. T., Frater, J. L., Klein, J., Chen, L., Bartlett, N. L., Foyil, K. V. & Kreisel, F. H., Jul 1 2016, In: Applied Immunohistochemistry and Molecular Morphology. 24, 6, p. 383-391 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Tumor-Infiltrating Lymphocytes 100%
  • Hodgkin Disease 94%
  • Reed-Sternberg Cells 92%
  • T-Lymphocytes 56%
  • Progression-Free Survival 47%
  10 Scopus citations

• Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study

  Chanan-Khan, A., Cramer, P., Demirkan, F., Fraser, G., Silva, R. S., Grosicki, S., Pristupa, A., Janssens, A., Mayer, J., Bartlett, N. L., Dilhuydy, M. S., Pylypenko, H., Loscertales, J., Avigdor, A., Rule, S., Villa, D., Samoilova, O., Panagiotidis, P., Goy, A., Mato, A., & 9 othersPavlovsky, M. A., Karlsson, C., Mahler, M., Salman, M., Sun, S., Phelps, C., Balasubramanian, S., Howes, A. & Hallek, M., Feb 1 2016, In: The Lancet Oncology. 17, 2, p. 200-211 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Bendamustine Hydrochloride 100%
  • PCI 32765 96%
  • Rituximab 70%
  • B-Cell Chronic Lymphocytic Leukemia 69%
  • Placebos 44%
  368 Scopus citations

• Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma

  Chen, R., Allibone, S., Bartlett, N. L., Brice, P., Chen, A., Pose, K., Rich, L., Bonthapally, V., Garfin, P. M. & Fanale, M., Apr 6 2016, In: OncoTargets and Therapy. 9, p. 2027-2034 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Brentuximab Vedotin 100%
  • Anaplastic Large-Cell Lymphoma 84%
  • Patient Reported Outcome Measures 68%
  • Hodgkin Disease 64%
  • Quality of Life 20%
  2 Scopus citations

• Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

  Ujjani, C. S., Jung, S. H., Pitcher, B., Martin, P., Park, S. I., Blum, K. A., Smith, S. M., Czuczman, M., Davids, M. S., Levine, E., Lewis, L. D., Smith, S. E., Bartlett, N. L., Leonard, J. P. & Cheson, B. D., Nov 24 2016, In: Blood. 128, 21, p. 2510-2516 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lenalidomide 100%
  • Ibrutinib 99%
  • PCI 32765 82%
  • Follicular Lymphoma 68%
  • Rituximab 60%
  46 Scopus citations

• Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227

  Glass, J., Won, M., Schultz, C. J., Brat, D., Bartlett, N. L., Suh, J. H., Werner-Wasik, M., Fisher, B. J., Liepman, M. K., Augspurger, M., Bokstein, F., Bovi, J. A., Solhjem, M. C. & Meh, M. P., May 10 2016, In: Journal of Clinical Oncology. 34, 14, p. 1620-1625 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Temozolomide 100%
  • Induction Chemotherapy 96%
  • Rituximab 87%
  • Methotrexate 77%
  • Lymphoma 66%
  94 Scopus citations

• The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and in Vivo Clearance of B Cell Lymphomas

  Rosario, M., Liu, B., Kong, L., Collins, L. I., Schneider, S. E., Chen, X., Han, K., Jeng, E. K., Rhode, P. R., Leong, J. W., Schappe, T., Jewell, B. A., Keppel, C. R., Shah, K., Hess, B., Romee, R., Piwnica-Worms, D. R., Cashen, A. F., Bartlett, N. L., Wong, H. C., & 1 othersFehniger, T. A., Feb 1 2016, In: Clinical Cancer Research. 22, 3, p. 596-608 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • ALT-803 100%
  • Interleukin-15 61%
  • B-Cell Lymphoma 49%
  • Natural Killer Cells 44%
  • Monoclonal Antibodies 11%
  117 Scopus citations

• US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816

  Press, O. W., Li, H., Schöder, H., Straus, D. J., Moskowitz, C. H., LeBlanc, M., Rimsza, L. M., Bartlett, N. L., Evens, A. M., Mittra, E. S., LaCasce, A. S., Sweetenham, J. W., Barr, P. M., Fanale, M. A., Knopp, M. V., Noy, A., Hsi, E. D., Cook, J. R., Lechowicz, M. J., Gascoyne, R. D., & 5 othersLeonard, J. P., Kahl, B. S., Cheson, B. D., Fisher, R. I. & Friedberg, J. W., Jun 10 2016, In: Journal of Clinical Oncology. 34, 17, p. 2020-2027 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Hodgkin Disease 100%
  • Positron-Emission Tomography 90%
  • Progression-Free Survival 32%
  • Bleomycin 20%
  • Doxorubicin 16%
  208 Scopus citations
• 2015

  A young woman with blurred vision and distal paresthesias

  Kung, N. H., Bartlett, N. L., Yaseen, N. R., Van Stavern, G. P. & Bucelli, R. C., Dec 2015, In: JAMA Neurology. 72, 12, p. 1519-1526 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Papilledema 100%
  • Polyneuropathies 94%
  • Ocular Vision 67%
  • Spinal Puncture 47%
  • Lower Extremity 32%

• Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression

  Jacobsen, E. D., Sharman, J. P., Oki, Y., Advani, R. H., Winter, J. N., Bello, C. M., Spitzer, G., Palanca-Wessels, M. C., Kennedy, D. A., Levine, P., Yang, J. & Bartlett, N. L., Feb 26 2015, In: Blood. 125, 9, p. 1394-1402 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Brentuximab Vedotin 100%
  • Lymphoma, Large B-Cell, Diffuse 70%
  • Refractory 64%
  • B-Lymphocyte Subsets 31%
  • Non-Hodgkin's Lymphoma 23%
  225 Scopus citations

• Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma

  Carson, K. R., Riedell, P., Lynch, R., Nabhan, C., Wildes, T. M., Liu, W., Ganti, A., Roop, R., Sanfilippo, K. M., O'Brian, K., Liu, J., Bartlett, N. L., Cashen, A., Wagner-Johnston, N., Fehniger, T. A. & Colditz, G. A., May 1 2015, In: Journal of Geriatric Oncology. 6, 3, p. 211-218 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Anthracyclines 100%
  • Lymphoma, Large B-Cell, Diffuse 98%
  • Veterans 91%
  • Drug Therapy 51%
  • Survival 21%
  42 Scopus citations

• Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: A randomized, double-blind, placebo-controlled phase 2b trial

  Fayad, L., Ansell, S. M., Advani, R., Coiffier, B., Stuart, R., Bartlett, N. L., Forero-Torres, A., Kuliczkowski, K., Belada, D., Ng, E. & Drachman, J. G., Sep 2 2015, In: Leukemia and Lymphoma. 56, 9, p. 2569-2578 10 p.

  Research output: Contribution to journal › Article › peer-review

  • dacetuzumab 100%
  • Ifosfamide 60%
  • Salvage Therapy 56%
  • Lymphoma, Large B-Cell, Diffuse 54%
  • Carboplatin 53%
  32 Scopus citations

• Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era

  Diefenbach, C. S., Li, H., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., Crump, M., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Stewart, D. A., Kahl, B. S., Friedberg, J. W., Blum, K. A., Habermann, T. M., Tuscano, J. M., Hoppe, R. T., Horning, S. J. & Advani, R. H., Nov 2015, In: British Journal of Haematology. 171, 4, p. 530-538 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Hodgkin Disease 100%
  • Age Factors 30%
  • Survival 30%
  • Hemoglobins 22%
  • Calibration 14%
  46 Scopus citations

• Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies

  Forero-Torres, A., Bartlett, N. L., Berryman, R. B., Chen, R., Matous, J. V., Fanale, M. A., O'Connor, O. A., Olshefski, R., Smith, S. E., Huebner, D., Levine, P. L., Grove, L. E. & Gopal, A. K., Apr 1 2015, In: Leukemia and Lymphoma. 56, 4, p. 1151-1153 3 p.

  Research output: Contribution to journal › Article › peer-review
  10 Scopus citations

• Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort

  Evens, A. M., Kanakry, J. A., Sehn, L. H., Kritharis, A., Feldman, T., Kroll, A., Gascoyne, R. D., Abramson, J. S., Petrich, A. M., Hernandez-Ilizaliturri, F. J., Al-Mansour, Z., Adeimy, C., Hemminger, J., Bartlett, N. L., Mato, A., Caimi, P. F., Advani, R. H., Klein, A. K., Nabhan, C., Smith, S. M., & 7 othersFabregas, J. C., Lossos, I. S., Press, O. W., Fenske, T. S., Friedberg, J. W., Vose, J. M. & Blum, K. A., Sep 1 2015, In: American journal of hematology. 90, 9, p. 778-783 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphoma, Large B-Cell, Diffuse 100%
  • Hodgkin Disease 91%
  • Rituximab 74%
  • Lymphoma 73%
  • Doxorubicin 45%
  66 Scopus citations

• Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

  Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Bartlett, N. L., Li, J., Simpson, D., Grosicki, S., Devereux, S., McCarthy, H., Coutre, S., Quach, H., Gaidano, G., Maslyak, Z., Stevens, D. A., Janssens, A., & 14 othersOffner, F., Mayer, J., O'Dwyer, M., Hellmann, A., Schuh, A., Siddiqi, T., Polliack, A., Tam, C. S., Suri, D., Cheng, M., Clow, F., Styles, L., James, D. F. & Kipps, T. J., Dec 17 2015, In: New England Journal of Medicine. 373, 25, p. 2425-2437 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • PCI 32765 100%
  • B-Cell Chronic Lymphocytic Leukemia 71%
  • Chlorambucil 59%
  • Progression-Free Survival 13%
  • Therapeutics 11%
  1175 Scopus citations

• Outcomes of transformed follicular lymphoma in the modern era: A report from the National LymphoCare Study (NLCS)

  Wagner-Johnston, N. D., Link, B. K., Byrtek, M., Dawson, K. L., Hainsworth, J., Flowers, C. R., Friedberg, J. W. & Bartlett, N. L., Aug 13 2015, In: Blood. 126, 7, p. 851-857 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Follicular Lymphoma 100%
  • Chemical Transformation 51%
  • Rituximab 44%
  • Confidence Intervals 32%
  • Vincristine 29%
  140 Scopus citations

• Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed Mycosis fungoides: SWOG 1108

  Barr, P. M., Li, H., Spier, C., Mahadevan, D., LeBlanc, M., Ul Haq, M., Huber, B. D., Flowers, C. R., Wagner-Johnston, N. D., Horwitz, S. M., Fisher, R. I., Cheson, B. D., Smith, S. M., Kahl, B. S., Bartlett, N. L. & Friedberg, J. W., Jul 20 2015, In: Journal of Clinical Oncology. 33, 21, p. 2399-2404 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • MLN 8237 100%
  • Peripheral T-Cell Lymphoma 77%
  • Mycosis Fungoides 72%
  • Non-Hodgkin's Lymphoma 53%
  • T-Cell Lymphoma 32%
  95 Scopus citations

• Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: A subset analysis of the North American Intergroup E2496 trial

  Advani, R. H., Hong, F., Fisher, R. I., Bartlett, N. L., Robinson, K. S., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Stewart, D. A., Gordon, L. I., Kahl, B. S., Friedberg, J. W., Blum, K. A., Habermann, T. M., Tuscano, J. M., Hoppe, R. T. & Horning, S. J., Jun 10 2015, In: Journal of Clinical Oncology. 33, 17, p. 1936-1942 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hodgkin Disease 100%
  • Radiotherapy 67%
  • Survival 32%
  • Vinblastine 23%
  • Bleomycin 22%
  27 Scopus citations

• Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)

  Leonard, J. P., Jung, S. H., Johnson, J., Pitcher, B. N., Bartlett, N. L., Blum, K. A., Czuczman, M., Giguere, J. K. & Cheson, B. D., Nov 1 2015, In: Journal of Clinical Oncology. 33, 31, p. 3635-3640 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Lenalidomide 100%
  • Follicular Lymphoma 92%
  • Rituximab 81%
  • Thrombosis 7%
  • B-Cell Lymphoma 4%
  146 Scopus citations

• Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)

  Morrison, V. A., Jung, S. H., Johnson, J., Lacasce, A., Blum, K. A., Bartlett, N. L., Pitcher, B. N. & Cheson, B. D., Apr 1 2015, In: Leukemia and Lymphoma. 56, 4, p. 958-964 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Lenalidomide 100%
  • Mantle-Cell Lymphoma 97%
  • Bortezomib 91%
  • Maintenance 26%
  • Survival 20%
  33 Scopus citations
• 2014

  Active idiotypic vaccination versus control immunotherapy for follicular lymphoma

  Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., Connors, J. M., Berinstein, N. L., Belch, A. R., Bartlett, N. L., Nichols, C., Emmanouilides, C. E., Timmerman, J. M., Gregory, S. A., Link, B. K., Inwards, D. J., Freedman, A. S., Matous, J. V., Robertson, M. J., Kunkel, L. A., & 6 othersIngolia, D. E., Gentles, A. J., Liu, C. L., Tibshirani, R., Alizadeh, A. A. & Denney, D. W., Jun 10 2014, In: Journal of Clinical Oncology. 32, 17, p. 1797-1803 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Follicular Lymphoma 100%
  • Immunotherapy 71%
  • Vaccination 65%
  • Progression-Free Survival 58%
  • keyhole-limpet hemocyanin 45%
  64 Scopus citations

• A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

  De Vos, S., Forero-Torres, A., Ansell, S. M., Kahl, B., Cheson, B. D., Bartlett, N. L., Furman, R. R., Winter, J. N., Kaplan, H., Timmerman, J., Whiting, N. C., Drachman, J. G. & Advani, R., Jun 12 2014, In: Journal of Hematology and Oncology. 7, 1, 44.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • dacetuzumab 100%
  • Lymphoma, Large B-Cell, Diffuse 54%
  • Chills 10%
  • Eye 9%
  • Conjunctivitis 9%
  70 Scopus citations

• Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: A retrospective evaluation of safety and efficacy

  Gopal, A. K., Bartlett, N. L., Forero-Torres, A., Younes, A., Chen, R., Friedberg, J. W., Matous, J. V., Shustov, A. R., Smith, S. E., Zain, J., O'Meara, M. M. & Fanale, M. A., Oct 1 2014, In: Leukemia and Lymphoma. 55, 10, p. 2328-2334 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Brentuximab Vedotin 100%
  • Lymphoma 52%
  • Safety 36%
  • Anaplastic Large-Cell Lymphoma 16%
  • Preexisting Condition Coverage 14%
  44 Scopus citations

• Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral t-cell lymphomas: Results of a phase i study

  Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., Chen, R. W., Davies, A., Illidge, T., Huebner, D., Kennedy, D. A. & Shustov, A. R., Oct 1 2014, In: Journal of Clinical Oncology. 32, 28, p. 3137-3143 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Brentuximab Vedotin 100%
  • Lymphoma 52%
  • Peripheral T-Cell Lymphoma 32%
  • Survival Rate 23%
  • Progression-Free Survival 21%
  143 Scopus citations

• CD163 Immunohistochemistry Is Superior to CD68 in Predicting Outcome in Classical Hodgkin Lymphoma

  Klein, J. L., Nguyen, T. D. T., Bien-Willner, G. A., Chen, L., Foyil, K. V., Bartlett, N. L., Duncavage, E. J., Hassan, A., Frater, J. L. & Kreisel, F., Mar 1 2014, In: American journal of clinical pathology. 141, 3, p. 381-387 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Hodgkin Disease 100%
  • Immunohistochemistry 67%
  • Macrophages 45%
  • Survival 26%
  • Multivariate Analysis 11%
  48 Scopus citations

• Commentary

  Bartlett, N. L., Feb 1 2014, In: Clinical Advances in Hematology and Oncology. 12, 2, p. 18-24 7 p.

  Research output: Contribution to journal › Article › peer-review

  1 Scopus citations

• Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: Multicentre, single-arm, phase 2 study

  Wang, M., Popplewell, L. L., Collins, R. H., Winter, J. N., Goy, A., Kaminski, M. S., Bartlett, N. L., Johnston, P. B., Lister, J., Fanning, S. R., Tuscano, J. M., Beck, J. T., Kaya, H., Robeva, A., Fan, J., Klimovsky, J., Cheung, W., Cherfi, A. & O'Connor, O. A., May 2014, In: British Journal of Haematology. 165, 4, p. 510-518 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Mantle-Cell Lymphoma 100%
  • Everolimus 96%
  • Bortezomib 93%
  • Progression-Free Survival 27%
  • Confidence Intervals 27%
  37 Scopus citations

• High incidence of methotrexate associated renal toxicity in patients with lymphoma: A retrospective analysis

  May, J., Carson, K. R., Butler, S., Liu, W., Bartlett, N. L. & Wagner-Johnston, N. D., Jun 2014, In: Leukemia and Lymphoma. 55, 6, p. 1345-1349 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Methotrexate 100%
  • Lymphoma 85%
  • Kidney 55%
  • Incidence 50%
  • Proton Pump Inhibitors 19%
  61 Scopus citations

• Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission

  Pingali, S. R., Jewell, S. W., Havlat, L., Bast, M. A., Thompson, J. R., Eastwood, D. C., Bartlett, N. L., Armitage, J. O., Wagner-Johnston, N. D., Vose, J. M. & Fenske, T. S., Jul 15 2014, In: Cancer. 120, 14, p. 2122-2129 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Hodgkin Disease 100%
  • Confidence Intervals 14%
  • Positron Emission Tomography Computed Tomography 13%
  • Tertiary Care Centers 10%
  • Signs and Symptoms 10%
  33 Scopus citations

• Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma

  Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y. & Bartlett, N. L., Mar 20 2014, In: Journal of Clinical Oncology. 32, 9, p. 912-918 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Rituximab 100%
  • Hodgkin Disease 94%
  • Progression-Free Survival 47%
  • B-Cell Lymphoma 27%
  • Therapeutics 15%
  100 Scopus citations

• Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

  Horwitz, S. M., Advani, R. H., Bartlett, N. L., Jacobsen, E. D., Sharman, J. P., O'Connor, O. A., Siddiqi, T., Kennedy, D. A. & Oki, Y., May 15 2014, In: Blood. 123, 20, p. 3095-3100 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Brentuximab Vedotin 100%
  • T-Cell Lymphoma 72%
  • Safety 53%
  • Refractory 43%
  • Progression-Free Survival 28%
  261 Scopus citations

• Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

  Bartlett, N. L., Chen, R., Fanale, M. A., Brice, P., Gopal, A., Smith, S. E., Advani, R., Matous, J. V., Ramchandren, R., Rosenblatt, J. D., Huebner, D., Levine, P., Grove, L. & Forero-Torres, A., Mar 19 2014, In: Journal of Hematology and Oncology. 7, 1, 24.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Brentuximab Vedotin 100%
  • Retreatment 76%
  • Hematologic Neoplasms 63%
  • Anaplastic Large-Cell Lymphoma 26%
  • Hodgkin Disease 20%
  133 Scopus citations

• The role of body mass index in survival outcome for lymphoma patients: US intergroup experience

  Hong, F., Habermann, T. M., Gordon, L. I., Hochster, H., Gascoyne, R. D., Morrison, V. A., Fisher, R. I., Bartlett, N. L., Stiff, P. J., Cheson, B. D., Crump, M., Horning, S. J. & Kahl, B. S., Mar 2014, In: Annals of Oncology. 25, 3, p. 669-674 6 p., mdt594.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphoma, Large B-Cell, Diffuse 100%
  • Lymphoma 94%
  • Body Mass Index 81%
  • Follicular Lymphoma 78%
  • Hodgkin Disease 65%
  40 Scopus citations
• 2013

  Anaplastic large-cell lymphoma with aberrant expression of multiple cytokeratins masquerading as metastatic carcinoma of unknown primary

  Nguyen, T. T., Kreisel, F. H., Frater, J. L. & Bartlett, N. L., Nov 20 2013, In: Journal of Clinical Oncology. 31, 33, p. e443-e445

  Research output: Contribution to journal › Article › peer-review
  21 Scopus citations